carbidopa has been researched along with Abnormal Movements in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 17 (41.46) | 24.3611 |
| 2020's | 15 (36.59) | 2.80 |
| Authors | Studies |
|---|---|
| Aldred, J; Anca-Herschkovitsch, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Gao, T; Iansek, R; Kovács, N; Kukreja, P; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Flisar, D; Kojović, M; Kolmančič, K; Kramberger, MG; Pirtošek, Z; Trošt, M; Zupančič, NK | 1 |
| Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á | 1 |
| Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Hegde, S; Odin, P; Pahwa, R; Parra, JC; Snedecor, SJ; Standaert, DG; Thakkar, S; Titova, N; Zadikoff, C | 1 |
| Amato, F; Artusi, CA; Calandra-Buonaura, G; Contin, M; Cortelli, P; Giannini, G; Imbalzano, G; Ledda, C; Lopiano, L; Olmo, G; Rinaldi, D; Romagnolo, A; Sambati, L; Zibetti, M | 1 |
| Aldred, J; Budur, K; Facheris, MF; Fisseha, N; Fung, VS; Hauser, RA; Jeong, A; Kimber, TE; Klos, K; Litvan, I; O'Neill, D; Robieson, WZ; Soileau, MJ; Spindler, MA; Standaert, DG; Talapala, S; Vaou, EO; Zheng, H | 1 |
| Iwaki, H; Mukai, Y; Nishikawa, N; Takahashi, Y | 1 |
| Horiba, M; Imamura, A; Kuroyanagi, G; Matsukawa, N; Murakami, H; Sakai, H; Sato, T; Takahashi, A; Ueki, Y; Usami, T | 1 |
| Ebersbach, G; Jost, WH; Kassubek, J; Klebe, S; Tönges, L | 1 |
| D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Aradi, SD; Hauser, RA | 1 |
| Fujioka, S; Komorita, S; Mishima, T; Nishida, A; Okajima, M; Tsuboi, Y | 1 |
| Barbato, LM; Freire-Alvarez, E; Kurča, E; Liu, Y; Lopez Manzanares, L; Pekkonen, E; Sánchez-Soliño, O; Spanaki, C; Vanni, P | 1 |
| Ammendolia, A; de Sire, A; Demeco, A; Marinaro, C; Moggio, L; Petraroli, A; Pino, I | 1 |
| Dinh, P | 1 |
| Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
| Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
| Ossig, C; Reichmann, H | 1 |
| Levin, OS; Liashchenko, EA; Skripkina, NA | 1 |
| Fedorova, NV; Kulua, TK | 1 |
| Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F | 1 |
| Antonini, A; Chaudhuri, KR; Fox, K; Fox, T; Honig, H; Martinez-Martin, P; Odin, P; Timpka, J | 1 |
| Bereczki, D; Nagy, H; Takáts, A; Toth, A; Wacha, J | 1 |
| Chang, FC; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Kwan, V; Mahant, N; Tsui, D; van der Poorten, D; Wolfe, N | 1 |
| Jog, MS; Kumar, N; Rizek, P | 1 |
| Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
| Babina, LA; Batysheva, TT; Boiko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaitsev, KA; Zhuravleva, EY | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Marconi, S; Stocchi, F | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Montgomery, EB | 1 |
| Jung, SK | 1 |
| Brodsky, MA; Hogarth, P; Nutt, JG | 1 |
| Nyholm, D | 1 |
| Antonini, A; Canesi, M; Dal Fante, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Pezzoli, G; Zibetti, M | 1 |
| Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
| Scheife, RT | 1 |
11 review(s) available for carbidopa and Abnormal Movements
| Article | Year |
|---|---|
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep | 2022 |
Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Arthroplasty, Replacement, Hip; Carbidopa; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Medical Management and Prevention of Motor Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Management; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Effects of rehabilitation on reducing dyskinesias in a Parkinson's disease patient abusing therapy with levodopa-carbidopa intestinal gel: a paradigmatic case report and literature review.
Topics: Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2013 |
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Dyskinesias; Gastrostomy; Gels; Humans; Intestines; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2015 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors | 2010 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Topics: Carbidopa; Dyskinesias; Gels; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Parkinson Disease | 2006 |
11 trial(s) available for carbidopa and Abnormal Movements
| Article | Year |
|---|---|
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Topics: Antiparkinson Agents; Carbidopa; Cellulitis; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2022 |
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
[Nocturnal symptoms of Parkinson's disease and approaches to their correction].
Topics: Carbidopa; Catechols; Drug Combinations; Dyskinesias; Humans; Levodopa; Muscle Cramp; Nocturia; Parkinson Disease; Restless Legs Syndrome | 2013 |
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Australia; Carbidopa; Dopamine Agents; Duodenum; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies; Psychomotor Performance; Quality of Life | 2016 |
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
19 other study(ies) available for carbidopa and Abnormal Movements
| Article | Year |
|---|---|
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
Topics: Carbidopa; Dopamine; Dyskinesias; Humans; Levodopa; Motor Cortex; Parkinson Disease | 2022 |
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies | 2022 |
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 2023 |
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
[New Therapeutic Options for the Individualised Titration of Levodopa].
Topics: Antiparkinson Agents; Carbidopa; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
[Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].
Topics: Activities of Daily Living; Carbidopa; Dyskinesias; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease | 2021 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome | 2015 |
Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dyskinesias; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Quality of Life | 2016 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors | 2010 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; France; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2005 |
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus | 2006 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |